Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EPOPROSTENOL Cause Interstitial lung disease? 37 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 37 reports of Interstitial lung disease have been filed in association with EPOPROSTENOL (EPOPROSTENOL). This represents 0.3% of all adverse event reports for EPOPROSTENOL.

37
Reports of Interstitial lung disease with EPOPROSTENOL
0.3%
of all EPOPROSTENOL reports
20
Deaths
29
Hospitalizations

How Dangerous Is Interstitial lung disease From EPOPROSTENOL?

Of the 37 reports, 20 (54.1%) resulted in death, 29 (78.4%) required hospitalization, and 4 (10.8%) were considered life-threatening.

Is Interstitial lung disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EPOPROSTENOL. However, 37 reports have been filed with the FAERS database.

What Other Side Effects Does EPOPROSTENOL Cause?

Dyspnoea (2,744) Headache (2,425) Diarrhoea (2,310) Nausea (2,016) Pain in jaw (1,928) Death (1,362) Flushing (1,256) Fatigue (1,133) Hospitalisation (1,078) Vomiting (1,068)

What Other Drugs Cause Interstitial lung disease?

METHOTREXATE (3,049) RITUXIMAB (2,458) PEMBROLIZUMAB (2,113) PREDNISONE (1,850) CYCLOPHOSPHAMIDE (1,725) NIVOLUMAB (1,538) AMIODARONE (1,421) DOXORUBICIN (1,352) ETANERCEPT (1,267) ADALIMUMAB (1,250)

Which EPOPROSTENOL Alternatives Have Lower Interstitial lung disease Risk?

EPOPROSTENOL vs EPTIFIBATIDE EPOPROSTENOL vs EPTINEZUMAB-JJMR EPOPROSTENOL vs EPTINEZUMAB\EPTINEZUMAB-JJMR EPOPROSTENOL vs EQUINE BOTULINUM NEUROTOXIN A/B/C/D/E/F/G IMMUNE FAB2 EPOPROSTENOL vs EQUINE THYMOCYTE IMMUNE GLOBULIN

Related Pages

EPOPROSTENOL Full Profile All Interstitial lung disease Reports All Drugs Causing Interstitial lung disease EPOPROSTENOL Demographics